MabVax Therapeutics Holdings Inc (MBVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH66770D
- Pages: 72
- November 2018
- Total Views:1145
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
MabVax Therapeutics Holdings Inc (MabVax Therapeutics) formerly known as Telik, Inc. is a clinical-stage biotechnology company that focuses on development of pipeline of human monoclonal antibody products for diagnosis and treatment of cancer. The company's research and development activities are focused on advancing its clinical advanced drug candidates, under the antibody and vaccine programs. The pipeline product candidates include HuMab-5B1, MVT-5873, MVT-2163 and MVT-1075. The company's vaccine programs candidates for bivalent vaccine, trivalent vaccine, pentavalent vaccine and multiple vaccines. The company has partnerships with academic institutions and also with pharmaceutical and biotechnology companies. MabVax Therapeutics is headquartered in San Diego, California, the US.
MabVax Therapeutics Holdings Inc (MBVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15
MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16
Partnerships 17
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Licensing Agreements 21
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
Equity Offering 24
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
Debt Offering 45
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Acquisition 46
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc-Key Competitors 48
MabVax Therapeutics Holdings Inc-Key Employees 49
MabVax Therapeutics Holdings Inc-Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 24, 2017: MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives 51
Financial Announcements 52
Apr 02, 2018: MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones 52
May 24, 2017: MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results 54
Corporate Communications 55
Aug 01, 2018: MabVax Therapeutics announces board of director changes 55
Jul 05, 2018: MabVax Therapeutics Receives Nasdaq Delist Determination 56
Jun 27, 2018: MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q 57
Apr 13, 2018: MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements 58
Feb 15, 2018: MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's USD 1.00 Minimum Bid Price Maintenance Requirement 59
Legal and Regulatory 60
Sep 21, 2018: Delaware Court of Chancery grants petition fied by MabVax Therapeutics 60
Sep 11, 2018: MabVax Therapeutics files suit against Sichenzia Ross Ference, a law firm that formerly represented the company in certain corporate, securities, and securities and exchange commission matters 61
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 62
Aug 03, 2018: Delaware Court of Chancery sets hearing date On petition filed By MabVax Therapeutics 63
Jul 27, 2018: MabVax Therapeutics Files Delaware Petition 64
Product News 65
09/13/2017: MabVax Therapeutics HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress 65
Product Approvals 66
Jan 09, 2017: MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 66
Clinical Trials 67
Jun 05, 2017: MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting 67
May 25, 2017: MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting 68
Feb 23, 2017: MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer 69
Feb 13, 2017: MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 70
Other Significant Developments 71
Jan 16, 2018: MabVax Therapeutics Holdings Provides Business Strategy Update 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List Of Figure
List of Figures
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15
MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc, Key Competitors 48
MabVax Therapeutics Holdings Inc, Key Employees 49
MabVax Therapeutics Holdings Inc, Subsidiaries 50
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
MabVax Therapeutics Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
MabVax Therapeutics Holdings Inc (MabVax Therapeutics) formerly known as Telik, Inc. is a clinical-stage biotechnology company that focuses on development of pipeline of human monoclonal antibody products for diagnosis and treatment of cancer. The company's research and development activities are focused on advancing its clinical advanced drug candidates, under the antibody and vaccine programs. The pipeline product candidates include HuMab-5B1, MVT-5873, MVT-2163 and MVT-1075. The company's vaccine programs candidates for bivalent vaccine, trivalent vaccine, pentavalent vaccine and multiple vaccines. The company has partnerships with academic institutions and also with pharmaceutical and biotechnology companies. MabVax Therapeutics is headquartered in San Diego, California, the US.
MabVax Therapeutics Holdings Inc (MBVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15
MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16
Partnerships 17
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Licensing Agreements 21
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
Equity Offering 24
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
Debt Offering 45
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Acquisition 46
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc-Key Competitors 48
MabVax Therapeutics Holdings Inc-Key Employees 49
MabVax Therapeutics Holdings Inc-Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 24, 2017: MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives 51
Financial Announcements 52
Apr 02, 2018: MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones 52
May 24, 2017: MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results 54
Corporate Communications 55
Aug 01, 2018: MabVax Therapeutics announces board of director changes 55
Jul 05, 2018: MabVax Therapeutics Receives Nasdaq Delist Determination 56
Jun 27, 2018: MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q 57
Apr 13, 2018: MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements 58
Feb 15, 2018: MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's USD 1.00 Minimum Bid Price Maintenance Requirement 59
Legal and Regulatory 60
Sep 21, 2018: Delaware Court of Chancery grants petition fied by MabVax Therapeutics 60
Sep 11, 2018: MabVax Therapeutics files suit against Sichenzia Ross Ference, a law firm that formerly represented the company in certain corporate, securities, and securities and exchange commission matters 61
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 62
Aug 03, 2018: Delaware Court of Chancery sets hearing date On petition filed By MabVax Therapeutics 63
Jul 27, 2018: MabVax Therapeutics Files Delaware Petition 64
Product News 65
09/13/2017: MabVax Therapeutics HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress 65
Product Approvals 66
Jan 09, 2017: MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075 66
Clinical Trials 67
Jun 05, 2017: MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting 67
May 25, 2017: MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting 68
Feb 23, 2017: MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer 69
Feb 13, 2017: MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 70
Other Significant Developments 71
Jan 16, 2018: MabVax Therapeutics Holdings Provides Business Strategy Update 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List Of Figure
List of Figures
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MabVax Therapeutics Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MabVax Therapeutics Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
MabVax Therapeutics Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Telik Raises USD5 Million in Venture Financing 13
Telik Raises USD4.6 Million in Venture Financing 14
Mabvax Therapeutics Raises USD 12 Million In Venture Financing 15
MabVax Therapeutics Raises USD 5.2 Million In First Tranche Of Series B Financing 16
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 17
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 18
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 19
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 20
Boehringer Ingelheim Enters into Licensing Agreement with MabVax Therapeutics 21
Y-mAbs Therapeutics Enters into Licensing Agreement with MabVax Therapeutics 22
MabVax Therapeutics Enters into Licensing Agreement with Life Technologies 23
MabVax Therapeutics to Raise USD0.9 Million in Private Placement of Shares 24
MabVax Therapeutics Raises USD2.1 Million in Private Placement of Shares 25
MabVax Therapeutics Files Registration Statement to Raise up to USD2.5 Million in Public Offering of Shares 27
MabVax Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 28
MabVax Therapeutics to Raise USD0.5 Million in Private Placement of Shares 29
MabVax Therapeutics to Raise USD1.3 Million in Private Placement of Shares 30
MabVax Therapeutics to Raise USD2 Million in Private Placement of Shares 31
MabVax Therapeutics Raises USD1.3 Million in Private Placement of Convertible Preferred Stock 32
MabVax Therapeutics Raises USD4.65 Million in Public Offering of Shares 33
MabVax Therapeutics Raises USD9.4 Million in Public Offering of Shares 35
MabVax Therapeutics Raises USD2.75 Million in Public Offering of Shares 37
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 38
MabVax Therapeutics Raises USD3 Million in Private Placement of Shares 40
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 41
MabVax Therapeutics Raises USD1.5 Million in Private Placement of Shares upon Exercise of Warrants 42
MabVax Therapeutics Raises USD2.5 Million in Private Placement of Shares 43
MabVax Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 44
MabVax Therapeutics Amends Private Placement of Notes Due 2018 for USD5.8 Million 45
Telik Completes Acquisition of MabVax Therapeutics, Oncology Therapies Provider 46
MabVax Therapeutics Holdings Inc, Key Competitors 48
MabVax Therapeutics Holdings Inc, Key Employees 49
MabVax Therapeutics Holdings Inc, Subsidiaries 50
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
MabVax Therapeutics Holdings Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
March 2021
Page 140 | November 2020
Page 99 | July 2020
Page 75 | July 2020
Page 114 | May 2020